Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. (PubMed, Leuk Lymphoma) - Oct 8, 2026 - P2, P3 | "NCT03222609 [REFINE]; NCT04468984 [TRANSFORM-2])."
Journal • Monotherapy • P2 data • P3 data • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology
|
|
Alessandro M Vannucchi; Andreas Reiter; Andrew Perkins; Atanas Radinoff; Claire N Harrison; Earle E Bain; Elza Lomaia; Fabrizio Pane; Francesca Palandri; Francesco Passamonti; Guray Saydam; Hun S Chuah; Hung Lam; Jacqueline S Garcia; Jalaja Potluri; Jean-Jacques Kiladjian; Kazuya Shimoda; Mehmet Turgut; Raajit K Rampal; Ruben Mesa; Shilpa Jain; Sung-Eun Lee; Sung-Soo Yoon
|